Ocular Therapeutix (OCUL) Q3 2025 TL;DR Summary
Ocular Therapeutix remains focused on its ELUTYX hydrogel technology pipeline, reporting significantly widening net losses driven by substantial investment in its lead asset, AXPAXLI. Management has certified the accuracy of the Form 10-Q filing for the period ended September 30, 2025.
Financial Performance & Liquidity Nine-month net loss accelerated to $201.3 million (up from $145.1 million last year), resulting in diluted EPS of $(1.15). Revenue declined 16.8% to $38.7 million, attributed to Medicare reimbursement pres
...